1 Introduction: 26RFa (QRFP) is a biologically active peptide that has been found to control 2 feeding behaviour by stimulating food intake, and to regulate glucose homeostasis by acting as 3 an incretin. The aim of the present study was thus to investigate the impact of 26RFa gene 4 knockout on the regulation of energy and glucose metabolism.
body weight and energy homeostasis in all vertebrates. Interestingly, a more sustained 1 orexigenic activity of 26RFa was reported in obese rodents (19, 23) . In addition, expression of 2 prepro26RFa mRNA is up-regulated in the hypothalamus of genetically obese ob/ob and db/db 3 mice (15), in rodents submitted to a high fat diet (19,23), and plasma levels of the neuropeptide 4 are increased in obese patients (24, 25) . Finally, 26RFa was found to trigger lipid uptake and to 5 inhibit lipolysis in obese individuals (26) . Altogether, these findings support the notion that 6 26RFa could play a role in the development and maintenance of the obese status (14) . 7 More recently, the implication of the 26RFa/GPR103 neuropeptidergic system in the control 8 of glucose homeostasis was reported. We, and others, found that 26RFa and GPR103 are 9 strongly expressed by β cells of the pancreatic islets (24, 25, 27) , and that the neuropeptide 10 prevents cell death and apoptosis of β cells (27) . We also showed that 26RFa is abundantly 11 expressed all along the gut and that i.p. administration of the neuropeptide attenuates glucose-12 induced hyperglycemia by increasing plasma insulin via a direct insulinotropic effect on the 13 pancreatic β cells, and by increasing insulin sensitivity (24, 25) . Finally, we reported that an oral 14 glucose challenge induces a massive secretion of 26RFa by the gut into the blood, strongly 15 suggesting that this neuropeptide regulates glycemia by acting as an incretin (24). This incretin 16 effect of 26RFa has been very recently confirmed by the observation that administration of a 17 GPR103 antagonist reduces the global glucose-induced incretin effect, and also decreases 18 insulin sensitivity (28). 19 Together, these findings support the idea that the 26RFa/GPR103 peptidergic system plays 20 an important role in the regulation of energy and glucose homeostasis. Consequently, the 21 objective of the present study was to investigate the impact of altered endogenous 26RFa 22 production on the regulation of energy and glucose metabolism using a model of mice 23 invalidated for the 26RFa gene.
Scales integrated into the sealed cage environment continuously measured cumulative food 1 intake and water intake. The mice were kept at a constant temperature of 23°C for 6 days. Body composition 4 Whole body composition was assessed on vigil animals, before and after metabolic parameters 5 measurement, using MiniSpec LF110 (Brucker, Wissembourg, France), a fast nuclear magnetic 6 resonance method. Blood glucose and insulin measurements in mice 9 For measurements of basal glycemia and insulinemia, mice were fasted 6 h before the test with 10 free access to water. For oral or i.p. glucose tolerance test, mice were fasted for 16 h with free 11 access to water and then treated i.p. or by gavage with glucose (2 g/kg) and 26RFa (500 μg/kg) Total RNA from livers of mice was isolated as previously described (28). Relative expression 24 of the glucose 6 phosphatase (G6PC), glucokinase (GCK) and phosphoenolpyruvate 25 carboxykinase 1 (PCK1) genes was quantified by real-time PCR with appropriate primers 26 (Table 1) . β-actin was used as internal control for normalization. PCR was carried out using Statistical analysis was performed with GraphPad Prism (6 th version). A student t-test or an 5 ANOVA one way were used for comparison between the groups. An ANOVA two ways was 3' (Corresponding to the iCre sequence). We detected a 361-pb product from wildtype allele 24 corresponding to the 26RFa coding sequence, and a 650-pb product from the targeted allele corresponding to the inserted iCre sequence (Suppl data 1B). Chimeric mice were crossed 1 with C57Bl/6J males (Janvier laboratory, Le Genest-Saint-Isle, France). Initially, F1 hybrids 2 from heterozygous x heterozygous mating were generated. 26RFa -/mice and wild type mice 3 littermates were basically obtained by heterozygous x heterozygous mating.
4
Immunohistochemical experiments performed on pancreas and duodenal sections revealed 5 the presence of an intense 26RFa-immunolabelling in the pancreatic islets and the duodenal 6 enterocytes of the wild type mice whereas similar sections from 26RFa-deficient mice were 7 totally devoid of staining ( Fig. 1A) . 12 revealed no significant difference between the wild type, heterozygous and 26RFa-KO mice 12 ( Fig. 1B-D) . Two-month old mice of the 3 groups also followed a 6-day protocol in which the 13 animals were fed ad libitum for 3 days, then were food-restricted for one day and refed for two 14 days. The body composition analysis showed that 26RFa -/-, 26RFa +/and 26RFa +/+ mice had 15 similar body weight, fat mass, lean mass and fluid mass, either at the beginning of the cession 16 or at the end of the protocol (Fig. 1E ).
17
Measurement of food intake all along the protocol did not reveal any significant difference 18 in the feeding behaviour of the 3 groups of mice although the 26RFa-KO and the heterozygous 19 mice ate a little bit more than the wild type controls ( Fig. 2A ). Evaluation of water intake 20 indicated the 26RFa -/mice drink significantly more than the wild type and the heterozygous 21 mice during the test (Fig. 2B ). Measurement of energy expenditure did not reveal any 22 significant variation between the 3 groups of mice although the 26RFa-deficient mice exhibited 23 a tendency to increased energy expenditure as compared to the wild type and heterozygous mice 24 ( Fig. 2C ). Metabolic rate measured as O2, CO2 and respiratory quotient was significantly higher type animals showed a drastic decrease of glucokinase (GCK) that promotes glycogen storage 1 and an upregulation of glucose 6 phosphatase (G6PC) and phosphoenolpyruvate carboxykinase 2 1 (PCK1) that trigger gluconeogenesis (Fig. 4D ). The 26RFa-deficient mice exhibited a 3 different expression profile in fasting condition with a slight decreased expression of GCK 4 associated with a robust increased expression of G6PC and PCK1 (Fig. 4E ).
6
Pancreatic phenotype of 26RFa-deficient mice 7 Comparison of freshly dissected pancreas indicated that the tissues of the 26RFa-KO mice were 8 bigger with more adipose tissues than the wild type and heterozygous mice although their 9 weights were similar in the 3 groups ( Fig. 5A, B ). We also observed that the number of 10 pancreatic islets per pancreas tended to be higher in the 26RFa +/and 26RFa -/mice, although 11 statistically not significant ( Fig. 5C ). In addition, the areas of the pancreatic islets were 12 significantly higher in the 26RFa-deficient mice as compared to the wild type mice (Fig. 5D ), 13 as illustrated by the photomicrographs shown in figure 5E . The quantitative analysis also 14 revealed that the total number of β cells per pancreas was significantly higher in the 26RFa -/-15 mice vs 26RFa +/+ mice (Fig. 5F ). Conversely, the number of α cells per islet was significantly 16 lower in the 26RFa +/and 26RFa -/mice vs 26RFa +/+ mice ( Fig. 5G ). Consequently, the ratio α 17 cells/β cells per islet was significantly lower in the heterozygous and KO mice as compared to 18 the wild type animals ( Fig. 5H ). Triple labelling experiments revealed that the intensity of the 19 insulin and glucagon immunostaining was much lower in the 26RFa-deficient mice vs wild type 20 animals, whereas, in the heterozygous mice the intensity of the immunostaining of the two 21 hormones was between the 26RFa -/and the 26RFa +/+ mice (Fig. 5I ). The iDISCO approach 22 confirmed that the intensity of the insulin immunostaining was much higher in the wild type 23 animals (video S1) in comparison to the 26RFa-KO mice (video S2).
Discussion 1
Accumulated data obtained during the last decade have promoted the evidence that the 2 neuropeptide 26RFa plays a key role in the control of feeding behaviour (10, 13, 14) and the 3 regulation of glucose homeostasis (24, 25, 27, 28). Supporting this notion, it has been recently 4 shown that acute administration of a GPR103 (the 26RFa receptor) antagonist decreases food 5 intake (30) and reduces the global glucose-induced incretin effect as well as the insulin 6 sensitivity (28). However, chronic deficiency of 26RFa signalling on energy and glucose 7 homeostasis remains to be elucidated. In the present study, we took advantage of a newly 8 generated mouse line deficient for the 26RFa gene to decipher the phenotype of the 26RFa -/-9 mice with regard to energy and glucose metabolism.
10
We first investigated the impact of chronic 26RFa depletion on various parameters of energy 11 metabolism. Our data reveal that 26RFa deficiency does not alter body weight gain from 12 postnatal week 5 to week 12. We also show that at 2 months, the 26RFa -/-, 26RFa +/and 13 26RFa +/+ mice exhibit a similar body composition in terms of body weight, fat and lean mass.
14 However, the 26RFa-KO mice show a basal energy expenditure slightly higher than the 15 heterozygous and their wild type littermates. In addition, the 26RFa-deficient mice tend to eat 16 and drink more than the wild type mice and exhibit a more elevated respiratory quotient 17 although their locomotor activity is not altered. Collectively, these observations suggest that 18 26RFa-deficient mice have a basal metabolic rate slightly higher than the wild type animals.
19
The observation that deletion of the 26RFa gene does not impair daily feeding behaviour and 20 body weight is not surprising as disruption of other major orexigenic peptides such as NPY or 21 ghrelin does not impact feeding behaviour (31, 32). Indeed, it is accepted that the congenital 22 lack of one regulatory peptide may be compensated by others as the control of feeding 23 behaviour is multifactorial. However, our data are in disagreement with a previous study 24 reporting that disruption of the 26RFa (QRFP) gene results in a lower body weight due to a hypophagic behaviour under both normal and high fat fed condition (33). We do not have any 1 obvious explanation for this discrepancy between the two studies except that the strains of 2 26RFa -/mice in the two studies are different (33, present study).
3
In the second part of our study, we have investigated the "glycemic" phenotype of the 4 26RFa-deficient mice. We first show that depletion of the 26RFa gene has no impact on the 5 evolution of glycemia and insulinemia measured in fed condition. Basal plasma glucose levels 6 are not altered in fasting condition in the 26RFa-KO mice too. However, fasted insulinemia is 7 significantly decreased in the 26RFa -/mice as compared to the 26RFa +/and 26RFa +/+ mice. In 8 addition, we show that, during a glucose tolerance test, the hyperglycemic peak is more 9 sustained in the mice deficient for 26RFa and this is associated with a lower rise in plasma 10 insulin, these effects being reversed by administration of exogenous 26RFa. By contrast, our 11 data indicate that insulin sensitivity is not affected by the absence of endogenous 26RFa.
12
Altogether, these findings reveal that depletion of 26RFa induces an alteration of glucose 13 homeostasis that is due to a defect in insulin secretion but not in insulin sensitivity. Consistent 14 with this finding, we have previously shown that 26RFa stimulates insulin secretion by the 15 pancreatic β cells (24) and that administration of a 26RFa receptor antagonist alters the anti-16 hyperglycemic response of the organism to a glucose challenge (28). Collectively, these data 17 confirm that 26RFa is an important regulator of glucose homeostasis.
18
Our data also reveal that depletion of 26RFa induces a dysfunction in the regulation of 19 glucose hepatic production. Indeed, the 26RFa-deficient mice exhibit an increase of their 20 glucose hepatic production that is associated with an up-regulation of G6PC and PCK1, two 21 key liver enzymes that trigger gluconeogenesis. We have previously reported that 26RFa exerts 22 a crucial anti-hyperglycemic effect that is due to its incretin activity and its insulin-sensitiviting 23 effect (24). Our present finding suggests that the inhibitory activity of 26RFa on hepatic glucose 24 production also participates to the global anti-hyperglycemic effect of the peptide. However, we have also previously shown that the 26RFa receptor GPR103 is not expressed in the liver 1 (24). This observation suggests that the inhibitory effect of 26RFa on glucose hepatic 2 production is not a direct effect but rather an indirect effect, maybe mediated via its insulin 3 secreting activity as insulin is well known to inhibit hepatic glucose production.
4
One major phenotype of the 26RFa-deficient mice is the low plasma insulin levels in fasting 5 conditions or in response to a glucose challenge. This led us to examine whether this decreased 6 insulin production was associated with alteration in the morphology and physiology of the 7 pancreas. Surprisingly, our quantitative analysis revealed that the pancreas of the mutant mice 8 are bigger with larger pancreatic islets than their wild type littermates with a higher number of 9 β cells/islet, that rather suggests an increased capacity of the pancreatic islets to produce and 10 secrete insulin in the 26RFa-deficient mice. However, 2D and 3D immunohistochemical 11 labeling of the pancreatic islets with insulin antibodies shows that the intensity of insulin 12 immunostaining in the β cells of the the 26RFa -/mice is much lower than that observed in 13 26RFa +/+ mice, suggesting that the capacity of the β cells to produce/secrete insulin is impaired 14 in the mutant mice. We hypothesize that this altered insulin production may explain the lower 15 plasma insulin levels observed in the 26RFa-deficient mice and that the increased number of 16 pancreatic islets and β cells observed in the mutant mice may reflect a compensatory mechanism 17 of the organism to counterbalance the low capacity of the β cells to produce insulin. We have 18 previously shown in human (25) and rodents (24) that the β cells of the pancreatic islets highly 19 express 26RFa. According to this latter observation, we think that a potential role for 26RFa in 20 the synthesis/production of insulin within the β cells deserves further investigation.
21
Finally, our experiments indicate that the heterozygous mice have an intermediate 22 "glycemic" phenotype between those of the mutant and the wild type animals.
23
In conclusion, the present study reveals that depletion of the 26RFa gene induces a 24 substantial alteration in the regulation of glucose homeostasis with, in particular, a deficit in insulin production by β cells of the pancreatic islets. These original data confirm and confirm 1 our previous studies (23, 24), supporting the idea that the neuropeptide 26RFa is a key regulator 2 of glucose homeostasis and that dysfunction of the 26RFa/GPR103 peptidergic system may 3 promote diabetes. 
